Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.32

+0.7%

Nov 5 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (220)	3/1/1999 2:01:00 PM
From: JFitnich	Read Replies (1) of 1475

One more time: I am reading and copying directly from the RS NOTE here. (1) Results of Phase 1 trial of MEDI507 in psoriasis patients expected by mid-99 (2)Initiation of Phase 2 trial of MEDI-507 in patients with GvHD expected in 4Q:99 That all it says. My guess is that the PH 2 will be evaluating what the drug can do in patients receiving it longer than 10 days, something they started to do with the PH 1/2 announced in December. Like I said, it's just a guess. I'm not sure if RStephens is wrong or they know something none of the rest of us know. JF

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next